Suzhou Highfine Biotech Co (SZSE:301393) Cash-to-Debt : 1,289.55 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Suzhou Highfine Biotech Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Suzhou Highfine Biotech Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 1,289.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Suzhou Highfine Biotech Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Suzhou Highfine Biotech Co's Cash-to-Debt or its related term are showing as below:

SZSE:301393' s Cash-to-Debt Range Over the Past 10 Years
Min: 34.05 Med: 236.1 Max: No Debt
Current: 1289.55

During the past 6 years, Suzhou Highfine Biotech Co's highest Cash to Debt Ratio was No Debt. The lowest was 34.05. And the median was 236.10.

SZSE:301393's Cash-to-Debt is ranked better than
93.43% of 1051 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs SZSE:301393: 1289.55

Suzhou Highfine Biotech Co Cash-to-Debt Historical Data

The historical data trend for Suzhou Highfine Biotech Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Suzhou Highfine Biotech Co Cash-to-Debt Chart

Suzhou Highfine Biotech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

34.05

N/A

111.49

1,137.70

Suzhou Highfine Biotech Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											139.72	236.10	5,798.75	1,137.70	1,289.55

Competitive Comparison of Suzhou Highfine Biotech Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suzhou Highfine Biotech Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Suzhou Highfine Biotech Co's Cash-to-Debt falls into.

Suzhou Highfine Biotech Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Suzhou Highfine Biotech Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1770.268	/	(0.831	+	0.725)
	=	1,137.70

Suzhou Highfine Biotech Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1777.001	/	(0.714	+	0.664)
	=	1,289.55

Suzhou Highfine Biotech Co (SZSE:301393) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Suzhou Highfine Biotech Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Suzhou Highfine Biotech Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Highfine Biotech Co (SZSE:301393) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suzhou Highfine Biotech Co Ltd (SZSE:301393) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

No. 32 Hongxi Road, F-12 Standard Factory Building, High-tech Zone, Jiangsu Province, Suzhou, CHN, 215151

Website

https://www.highfine.com

Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.

Suzhou Highfine Biotech Co (SZSE:301393) Headlines

No Headlines